Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
Autore:
Braun, S; Kentenich, C; Janni, W; Hepp, F; de Waal, J; Willgeroth, F; Sommer, H; Pantel, K;
Indirizzi:
Univ Munich, Frauenklin 1, Klinikum Innenstadt, D-80337 Munich, Germany Univ Munich Munich Germany D-80337 m Innenstadt, D-80337 Munich, Germany Kreiskrankenhaus, Abt Gynakol, Dachau, Germany Kreiskrankenhaus Dachau Germany ankenhaus, Abt Gynakol, Dachau, Germany Univ Hamburg, Klinikum Eppendorf, Frauenklin, Hamburg, Germany Univ Hamburg Hamburg Germany um Eppendorf, Frauenklin, Hamburg, Germany
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 1, volume: 18, anno: 2000,
pagine: 80 - 86
SICI:
0732-183X(200001)18:1<80:LOEOAC>2.0.ZU;2-4
Fonte:
ISI
Lingua:
ENG
Soggetto:
EPITHELIAL MEMBRANE ANTIGEN; MONOCLONAL-ANTIBODY; PREMENOPAUSAL WOMEN; PROGNOSTIC VALUE; PRIMARY SURGERY; FOLLOW-UP; MICROMETASTASES; THERAPY; RADIOTHERAPY; BLOOD;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Braun, S Univ Munich, Frauenklin 1, Klinikum Innenstadt, Maistr 11, D-80337 Munich,Germany Univ Munich Maistr 11 Munich Germany D-80337 0337 Munich,Germany
Citazione:
S. Braun et al., "Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients", J CL ONCOL, 18(1), 2000, pp. 80-86

Abstract

Purpose: There is an urgent need for markers that can predict the efficacyof adjuvant chemotherapy in patients with solid tumors. This study was designed to evaluate whether monitoring of micrometastases in bone marrow can predict the response to systemic chemotherapy in breast cancer. Patients and Methods: Bone marrow aspirates of 59 newly diagnosed breast cancer patients with either inflammatory (n = 23) or advanced (> four nodes involved) disease (n = 36) were examined immunocytochemically with the monoclonal anticytokeratin (CK) antibody A45-B/B3 (murine immunoglobulin G(1); Micromet, Munich, Germany) before and after chemotherapy with taxanes and anthracyclines. Results: Of 59 patients, 29 (49.2%) and 26 (44.1%) presented with CK-positive tumor cells in bone marrow before and after chemotherapy, respectively. After chemotherapy, less than half of the previously CK-positive patients (14 of 29 patients; 48.3%) had a CK-negative bone marrow finding, and 11 (36.7%) of 30 previously CK-negative patients were CK-positive. At a median follow-up of 19 months (range, 6 to 39 months), Kaplan-Meier analysis of 55 assessable patients revealed a significantly reduced overall survival (P = .011; log-rank test) if CK-positive cells were detected after chemotherapy. In multivariate analysis, the presence of CK-positive tumor cells in bone marrow after chemotherapy was an independent predictor for reduced overall survival (relative risk = 5.0; P = .016). Conclusion: The cytotoxic agents currently used for chemotherapy in high-risk breast cancer patients do not completely eliminate CK-positive tumor cells in bone marrow. The presence of these tumor cells after chemotherapy isassociated with poor prognosis. Thus, bone marrow monitoring might help predict the response to systemic chemotherapy. (C) 2000 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 15:27:25